Trial Condition(s):

Prostatic Neoplasms

Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastases

Bayer Identifier:

16216

ClinicalTrials.gov Identifier:

NCT01618370

EudraCT Number:

2012-000075-16

Study Completed

Trial Purpose

This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product.

Inclusion Criteria
- Age ≥18 years of age
 - Histologically or cytologically confirmed prostate cancer
 - Patients diagnosed with progressive bone predominant metastatic CRPC/HRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) with at least 2 skeletal metastases on imaging with no lung, liver, and/or brain metastasis (lymph node only metastasis is allowed) 
 - Progressive disease is defined either by:
 -- The appearance of new bone lesions. If progression is based on new lesion(s) on imaging only without an increase in prostate specific antigen (PSA), PSA values from 3 assessments within the last 6 months must be provided;   OR
 -- In the absence of new bone lesions by 2 subsequent increases in serum PSA over previous reference value, which should not be more than 6 months before screening, each measured at least 1 week apart with the last PSA ≥ 5 ng/mL. (The reference value time point 1, is defined as the last PSA measured before increases are documented, with subsequent values obtained a minimum of 1 week apart. If the PSA at time point 3 is greater than the PSA at time point 2, then eligibility has been met. If the PSA at time point 3 is not greater than the PSA at time point 2 but the PSA value at time point 4 and/or time point 5 is greater than the PSA at time point 2, the patient is eligible assuming that other criteria are met) 
 - Life expectancy ≥ 6 months
 - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 - 2
 - Adequate hematological, liver, and renal function
 -- Absolute neutrophil count (ANC) ≥ 1.5 x10^9/L
 -- Platelet count ≥ 100 x10^9/L 
 -- Hemoglobin ≥ 10.0 g/dL (100 g/L; 6.2 mmol/L)
 -- Total bilirubin level ≤ 1.5 x institutional upper limit of normal (ULN)
 -- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN 
 -- Creatinine ≤ 1.5 x ULN
 -- Albumin > 25 g/L
Exclusion Criteria
- Treatment with an investigational drug within previous 4 weeks, or planned during the treatment period or follow-up
 - Eligible for first course of docetaxel, i.e., patients who are fit enough, willing, and who are located where treatment with docetaxel is available
 - Treatment with cytotoxic chemotherapy within previous 4 weeks, or failure to recover from AEs (adverse events) due to cytotoxic chemotherapy administered more than 4 weeks previous (however, ongoing neuropathy is permitted)
 - Prior hemibody external radiotherapy is excluded.  Patients who received other types of prior external radiotherapy are allowed provided that the bone marrow function is assessed and meets the protocol requirements for hemoglobin, absolute neutrophil count and platelets
 - Received systemic therapy with radionuclides (e.g., strontium-89, samarium-153, rhenium-186, or rhenium-188, or radium-223 dichloride) for the treatment of bony metastases
 - Other malignancy treated within the last 3 years (except non melanoma skin cancer or low-grade superficial bladder cancer)
 - Visceral metastases as assessed by abdominal or pelvic computed tomography (CT) (or other imaging modality based on institutional standard of care)
 - Presence of brain metastases
 - Lymphadenopathy exceeding 6 cm in short-axis diameter
 - Any size pelvic lymphadenopathy if it is thought to be a contributor to concurrent hydronephrosis
 - Imminent or history of spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI). Patients with history of spinal cord compression should have completely recovered.
 - Any other serious illness or medical condition, such as but not limited to:
 -- Any infection ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 Grade 2 
 -- Cardiac failure New York Heart Association (NYHA) III or IV
 -- Crohn’s disease or ulcerative colitis
 -- Bone marrow dysplasia
 - Fecal incontinence

Trial Summary

Enrollment Goal
705
Trial Dates
black-arrow
Phase
3
Could I receive a placebo?
No
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Berlin, Germany, 12200

Status
Completed
 
Locations

Investigative Site

Dresden, Germany, 01307

Status
Completed
 
Locations

Investigative Site

Aachen, Germany, 52074

Status
Completed
 
Locations

Investigative Site

Frankfurt, Germany, 60590

Status
Completed
 
Locations

Investigative Site

München, Germany, 81377

Status
Completed
 
Locations

Investigative Site

München, Germany, 81675

Status
Completed
 
Locations

Investigative Site

Mainz, Germany, 55131

Status
Completed
 
Locations

Investigative Site

Rostock, Germany, 18107

Status
Completed
 
Locations

Investigative Site

Berlin, Germany, 14197

Status
Completed
 
Locations

Investigative Site

Bremen, Germany, 28277

Status
Completed
 
Locations

Investigative Site

Erlangen, Germany, 91054

Status
Completed
 
Locations

Investigative Site

Magdeburg, Germany, 39120

Status
Completed
 
Locations

Investigative Site

Tübingen, Germany, 72076

Status
Completed
 
Locations

Investigative Site

Stockholm, Sweden, 171 76

Status
Completed
 
Locations

Investigative Site

Jena, Germany, 07740

Status
Completed
 
Locations

Investigative Site

Düsseldorf, Germany, 40225

Status
Completed
 
Locations

Investigative Site

Lund, Sweden, 221 85

Status
Completed
 
Locations

Investigative Site

Uppsala, Sweden, 751 85

Status
Completed
 
Locations

Investigative Site

Linköping, Sweden, 581 85

Status
Completed
 
Locations

Investigative Site

Umeå, Sweden, 901 85

Status
Completed
 
Locations

Investigative Site

Kalmar, Sweden, 391 85

Status
Completed
 
Locations

Investigative Site

Sundsvall, Sweden, 851 86

Status
Completed
 
Locations

Investigative Site

Eskilstuna, Sweden, 633 52

Status
Completed
 
Locations

Investigative Site

Karlstad, Sweden, 651 85

Status
Completed
 
Locations

Investigative Site

Beer Sheva, Israel, 8410101

Status
Completed
 
Locations

Investigative Site

Kfar Saba, Israel, 4428164

Status
Completed
 
Locations

Investigative Site

Haifa, Israel, 3109601

Status
Completed
 
Locations

Investigative Site

Zerifin, Israel, 6093000

Status
Completed
 
Locations

Investigative Site

Jerusalem, Israel, 9112001

Status
Completed
 
Locations

Investigative Site

Petah Tikva, Israel, 4941492

Status
Completed
 
Locations

Investigative Site

Tel Aviv, Israel, 6423906

Status
Completed
 
Locations

Investigative Site

Galway, Ireland

Status
Completed
 
Locations

Investigative Site

Dublin 6, Ireland

Status
Completed
 
Locations

Investigative Site

Cork, Ireland

Status
Completed
 
Locations

Investigative Site

Meldola, Italy, 47014

Status
Completed
 
Locations

Investigative Site

Milano, Italy, 20133

Status
Completed
 
Locations

Investigative Site

Pisa, Italy, 56126

Status
Completed
 
Locations

Investigative Site

Lausanne, Switzerland, 1011

Status
Completed
 
Locations

Investigative Site

St. Gallen, Switzerland, 9007

Status
Completed
 
Locations

Investigative Site

Chur, Switzerland, 7000

Status
Completed
 
Locations

Investigative Site

Aarau, Switzerland, 5001

Status
Completed
 
Locations

Investigative Site

Basel, Switzerland, 4056

Status
Completed
 
Locations

Investigative Site

Bern, Switzerland, 3010

Status
Completed
 
Locations

Investigative Site

Zürich, Switzerland, 8091

Status
Completed
 
Locations

Investigative Site

Helsinki, Finland, 00180

Status
Completed
 
Locations

Investigative Site

Tampere, Finland, FIN-33520

Status
Completed
 
Locations

Investigative Site

HUS, Finland, 00029

Status
Completed
 
Locations

Investigative Site

Seinäjoki, Finland, 60220

Status
Completed
 
Locations

Investigative Site

Kuopio, Finland, 70210

Status
Completed
 
Locations

Investigative Site

Lørenskog, Norway, 1478

Status
Completed
 
Locations

Investigative Site

Bodø, Norway, 8092

Status
Completed
 
Locations

Investigative Site

Bergen, Norway, 5021

Status
Completed
 
Locations

Investigative Site

Oslo, Norway, 0424

Status
Completed
 
Locations

Investigative Site

Ålesund, Norway, 6026

Status
Completed
 
Locations

Investigative Site

Plymouth, United Kingdom, PL6 8DH

Status
Completed
 
Locations

Investigative Site

Milano, Italy, 20089

Status
Completed
 
Locations

Investigative Site

Roma, Italy, 00161

Status
Completed
 
Locations

Investigative Site

Messina, Italy, 98125

Status
Completed
 
Locations

Investigative Site

Barcelona, Spain, 08035

Status
Completed
 
Locations

Investigative Site

Pamplona, Spain, 31008

Status
Completed
 
Locations

Investigative Site

Madrid, Spain, 28033

Status
Completed
 
Locations

Investigative Site

Santiago de Compostela, Spain, 15706

Status
Completed
 
Locations

Investigative Site

Malaga, Spain, 29010

Status
Completed
 
Locations

Investigative Site

Madrid, Spain, 28007

Status
Completed
 
Locations

Investigative Site

ZWOLLE, Netherlands, 8025 AB

Status
Completed
 
Locations

Investigative Site

NIJMEGEN, Netherlands, 6525 GA

Status
Completed
 
Locations

Investigative Site

Örebro, Sweden, 715 92

Status
Completed
 
Locations

Investigative Site

Bebington, United Kingdom, CH63 4JY

Status
Completed
 
Locations

Investigative Site

Berlin, Germany, 10719

Status
Completed
 
Locations

Investigative Site

Marburg, Germany, 35043

Status
Completed
 
Locations

Investigative Site

Freiburg im Breisgau, Germany, 79106

Status
Completed
 
Locations

Investigative Site

Nottingham, United Kingdom, NG5 1PB

Status
Completed
 
Locations

Investigative Site

Torino, Italy, 10043

Status
Completed
 
Locations

Investigative Site

Genova, Italy, 16128

Status
Completed
 
Locations

Investigative Site

Ulm, Germany, 89075

Status
Completed
 
Locations

Investigative Site

Hamburg, Germany, 20246

Status
Completed
 
Locations

Investigative Site

Barcelona, Spain, 08025

Status
Completed
 
Locations

Investigative Site

Barcelona, Spain, 08036

Status
Completed
 
Locations

Investigative Site

Palma de Mallorca, Spain, 07120

Status
Completed
 
Locations

Investigative Site

Madrid, Spain, 28046

Status
Completed
 
Locations

Investigative Site

Córdoba, Spain, 14004

Status
Completed
 
Locations

Investigative Site

Hospitalet de Llobregat, Spain, 08907

Status
Completed
 
Locations

Investigative Site

Manchester, United Kingdom, M20 4BX

Status
Completed
 
Locations

Investigative Site

Belfast, United Kingdom, BT9 7AB

Status
Completed
 
Locations

Investigative Site

Coventry, United Kingdom, CV2 2DX

Status
Completed
 
Locations

Investigative Site

London, United Kingdom, SE1 9RT

Status
Completed
 
Locations

Investigative Site

Guildford, United Kingdom, GU2 7XX

Status
Completed
 
Locations

Investigative Site

Warszawa, Poland, 02-781

Status
Completed
 
Locations

Investigative Site

Treviso, Italy, 31100

Status
Completed
 
Locations

Investigative Site

Arezzo, Italy, 52100

Status
Completed
 
Locations

Investigative Site

Trento, Italy, 38122

Status
Completed
 
Locations

Investigative Site

Roma, Italy, 00189

Status
Completed
 
Locations

Investigative Site

Roma, Italy, 00149

Status
Completed
 
Locations

Investigative Site

Toronto, Canada, M5G 2M9

Status
Completed
 
Locations

Investigative Site

Vancouver, Canada, V5Z 4E6

Status
Completed
 
Locations

Investigative Site

Toronto, Canada, M4N 3M5

Status
Completed
 
Locations

Investigative Site

BRUXELLES - BRUSSEL, Belgium, 1200

Status
Completed
 
Locations

Investigative Site

BRUXELLES - BRUSSEL, Belgium, 1000

Status
Completed
 
Locations

Investigative Site

GENT, Belgium, 9000

Status
Completed
 
Locations

Investigative Site

LEUVEN, Belgium, 3000

Status
Completed
 
Locations

Investigative Site

BRUXELLES - BRUSSEL, Belgium, 1090

Status
Completed
 
Locations

Investigative Site

Ramat Gan, Israel, 5262000

Status
Completed
 
Locations

Investigative Site

Bialystok, Poland, 15-027

Status
Completed
 
Locations

Investigative Site

Santander, Spain, 39008

Status
Completed
 
Locations

Investigative Site

Madrid, Spain, 28041

Status
Completed
 
Locations

Investigative Site

Sevilla, Spain, 41013

Status
Completed
 
Locations

Investigative Site

Oviedo, Spain, 33006

Status
Completed
 
Locations

Investigative Site

Valencia, Spain, 46026

Status
Completed
 
Locations

Investigative Site

Ottawa, Canada, K1H 8L6

Status
Completed
 
Locations

Investigative Site

Montreal, Canada, H2L 4M1

Status
Completed
 
Locations

Investigative Site

Obninsk, Russia, 249036

Status
Completed
 
Locations

Investigative Site

Moscow, Russia, 115478

Status
Completed
 

Trial Design